SNS-314
SNS-314 was discovered at Sunesis. SNS-314 works by interfering with cancer cell division, which causes the cancer cell to die. The first study in cancer patients enrolling patients. People who have advanced solid tissue tumors will be eligible for this study.
Get general information about clinical studies, and learn about Sunesis investigational drugs currently in clinical trial.
Sunesis is an innovative biopharmaceutical company focused on therapeutics for oncology and other unmet medical needs.
Copyright © Sunesis Pharmaceuticals, Inc. 2007. All Rights Reserved.